Related Experiment Video

Updated: Sep 17, 2025

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.4K

Sodium Glucose Cotransporter 2 Inhibitors Across the Spectrum of Cardiovascular Kidney Metabolic Syndrome

Kevin Bryan Lo1, Karim Iskarous2, Rajiv Sankaranarayanan3

  • 1Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02114, USA.

Cardiology Clinics
|June 29, 2025
PubMed

Insights

Rising metabolic diseases like diabetes and obesity are linked to cardiovascular and kidney issues. Sodium glucose cotransporter 2 inhibitors (SGLT2i) show significant benefits for patients with cardiovascular kidney metabolic (CKM) syndrome.

Area of Science:

  • Metabolic diseases
  • Cardiovascular health
  • Renal function

Background:

  • Increasing global burden of metabolic diseases such as diabetes and obesity.
  • Dysfunctional adipose tissue contributes to inflammation and insulin resistance.
  • These factors precipitate cardiovascular kidney metabolic (CKM) syndrome.

Purpose of the Study:

  • To summarize the mechanisms of action for Sodium-glucose cotransporter 2 inhibitors (SGLT2i).
  • To review clinical evidence supporting SGLT2i use in CKM syndrome.
  • To highlight SGLT2i benefits across the CKM spectrum.

Main Methods:

  • Review of existing scientific literature and clinical trial data.
  • Analysis of pharmacological actions of SGLT2 inhibitors.
  • Synthesis of evidence on SGLT2i efficacy in metabolic, cardiac, and renal disease.

Main Results:

  • SGLT2 inhibitors demonstrate multifaceted benefits.
  • Evidence supports their role in improving glycemic control, cardiovascular outcomes, and kidney function.
  • Consistent efficacy observed across diverse patient populations within CKM syndrome.

Conclusions:

  • SGLT2 inhibitors are pivotal in managing CKM syndrome.
  • Their mechanisms address key pathophysiological pathways.
  • Clinical data strongly support their therapeutic role.
Keywords:
CKMCardiometabolicCardiorenalCardiovascular kidney metabolic syndromeSGLT2i

More Related Videos

Simple Continuous Glucose Monitoring in Freely Moving Mice03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

6.1K
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.9K

Related Concept Videos

Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
125.3K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
272
Transcellular Transport of Solutes01:23

Transcellular Transport of Solutes

Transcellular transport of solutes is the movement of substances like monosaccharides and amino acids through polarized cells. This transport mechanism is primarily seen in epithelial and endothelial cells aided by membrane transport proteins such as channels and transporters. The tight junctions between these cells confine the membrane proteins to the two sides of the cell. The epithelial cells have distinct apical and basolateral domains. In contrast, the endothelial cells show the luminal...
3.9K